Patients with moderate-to-severe psoriasis may have a significantly worse health-related quality of life (HRQoL). For a study, researchers aimed to compared and link improvements in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) ratings between patients receiving guselkumab vs placebo or adalimumab. Phase III pooled Data from VOYAGE 1 and VOYAGE 2 were analyzed through week 24. Patients were randomly assigned to receive guselkumab 100 mg, placebo, or adalimumab 40 mg at the start of the study. Patients on placebo were transferred to guselkumab at week 16. DLQI percent change from baseline, DLQI 0/1, DLQI minimum clinically meaningful difference (MCID), individual domain scores, PSSD symptoms, and signs score=0, DLQI connection with PSSD, Investigator’s Global Assessment (IGA), and Psoriasis Area and Severity Index (PASI).
Guselkumab significantly outperformed placebo in terms of improvement from baseline DLQI (weeks 8 and 16) and adalimumab in terms of improvement from baseline (week 24; P<0.001). At week 24, the proportion of patients who achieved DLQI 0/1 (“no impact”) was greater with guselkumab than with adalimumab (58.9 vs. 40.2%; P<0.001), and more patients achieved a 4-point decrease in DLQI (MCID) (P<0.001). Individual DLQI domain changes were significantly greater for patients receiving guselkumab than for those receiving adalimumab, and among patients with individual baseline domain scores=3 or 6 (most severe impact), more guselkumab recipients than adalimumab recipients achieved a score=0 across all domains at week 24. DLQI 0/1 scores were related to a PSSD symptom or sign score of 0 (no impact) and better PASI and IGA improvement (week 24).
Data from the VOYAGE 1/VOYAGE 2 trials showed that guselkumab outperformed adalimumab in terms of increasing HRQoL, which was related to higher skin clearing.